$0.96
7.68% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US74065P1012
Symbol
PRLD
Sector
Industry

Prelude Therapeutics Inc Stock price

$0.96
-0.04 3.99% 1M
+0.16 20.01% 6M
-0.31 24.70% YTD
-2.94 75.38% 1Y
-18.04 94.95% 5Y
-18.04 94.95% 10Y
-18.04 94.95% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.08 7.68%
ISIN
US74065P1012
Symbol
PRLD
Sector
Industry

Key metrics

Market capitalization $58.72m
Enterprise Value $-40.30m
EV/FCF (TTM) EV/FCF 0.38
P/B ratio (TTM) P/B ratio 0.57
Free Cash Flow (TTM) Free Cash Flow $-105.85m
Cash position $99.07m
P/E forward negative
Short interest 12.81%

Is Prelude Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Prelude Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Prelude Therapeutics Inc forecast:

3x Buy
75%
1x Sell
25%

Analyst Opinions

4 Analysts have issued a Prelude Therapeutics Inc forecast:

Buy
75%
Sell
25%

Financial data from Prelude Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
7 7
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 29 29
1% 1%
410%
- Research and Development Expense 118 118
14% 14%
1,686%
-138 -138
5% 5%
-1,971%
- Depreciation and Amortization 1.77 1.77
51% 51%
25%
EBIT (Operating Income) EBIT -140 -140
6% 6%
-1,996%
Net Profit -127 -127
4% 4%
-1,817%

In millions USD.

Don't miss a Thing! We will send you all news about Prelude Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Prelude Therapeutics Inc Stock News

Neutral
GlobeNewsWire
12 days ago
WILMINGTON, Del., June 02, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June.
Neutral
GlobeNewsWire
about one month ago
PRT3789 monotherapy and combination with docetaxel escalation enrollment is complete and the Company plans to present updated results in the second half of 2025 Enrollment of the Phase 1 study of Prelude's once daily, oral SMARCA2 degrader, PRT7732 is advancing rapidly, and an initial data update is anticipated in the second half of 2025 Current cash runway into the second quarter of 2026 with ...
Neutral
GlobeNewsWire
about one month ago
WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens Life Sciences Conference taking place in New York on May 7, 2025.
More Prelude Therapeutics Inc News

Company Profile

Prelude Therapeutics, Inc. operates as a cancer drug discovery company. It focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Gopi Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.

Head office United States
CEO Krishna Vaddi
Employees 131
Founded 2016
Website preludetx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today